Albumin Inhibitors
1 drugsAbout Albumin
Albumin, the most abundant protein in blood plasma, maintains osmotic pressure and transports molecules. Its long half-life and binding capacity make it relevant to drug pharmacokinetics and targeted delivery.
Albumin is emerging as a drug target to improve drug bioavailability and reduce off-target effects. Currently, there is no genetic evidence directly linking albumin to specific diseases.
Albumin is targeted by one FDA-approved drug, OPTISON, a small molecule with 12 indications. GE HEALTHCARE is the only company with an approved albumin-targeting drug.
Top Albumin Drugs
GE HEALTHCARE is the only company with an approved drug targeting Albumin.
Low market concentration suggests low barriers to entry for new competitors.
Albumin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Albumin, using small molecule modality.
The modality landscape suggests an opportunity to explore alternative modalities like antibodies or fusion proteins.
Albumin Clinical Trials 50 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Albumin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 4 | 1 | 0 | 80% |
| Phase 2 | 14 | 5 | 7 | 2 | 42% |
| Phase 3 | 14 | 7 | 2 | 5 | 78% |
| Phase 4 | 17 | 11 | 4 | 2 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Albumin Drug Approval Timeline (1997 - 1997)
The first and only drug, OPTISON, was approved in 1997.
The approval timeline indicates a saturated market with no recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 43 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Albumin. A trial counts if an approved drug acting on Albumin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.